Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TL139 in advanced or metastatic solid tumors with NTRK, ROS1, or ALK fusions
CTR20202551Phase 2Active
- Sponsor
- Taolue Biopharma
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TL139 in Nonhematologic neoplasms, sponsored by Taolue Biopharma. Started Dec 2020; status: active.
02
Drugs
TL139
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20202551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202551.